No Data
China Resources Boya Bio-Pharmaceutical Group (300294.SZ): The company's products are not related to stem cells.
On December 2, Gelonghui reported that china resources boya bio-pharmaceutical group (300294.SZ) stated on the investor interaction platform that the company is mainly engaged in the research and development, production, and sales of blood products. Blood products refer to plasma protein products extracted from healthy human plasma through separation and purification methods. The company's products are not related to stem cells.
China Resources Boya Bio-Pharmaceutical Group (300294.SZ): 78.3086 million restricted shares will be unlocked on November 25th.
On November 19, Gelonghui announced that china resources boya bio-pharmaceutical group (300294.SZ) published a notice regarding the lifting of restrictions on the issuance of stocks to specific entities. The number of shares applying for unrestricted trading is 78,308,575 shares issued by china resources boya bio-pharmaceutical group limited (hereinafter referred to as the company) to specific entity chinares pharma holdings limited. This number of unrestricted shares accounts for 15.5298% of the company's total stock capital; after lifting the restrictions, the actual number of shares available for trading will be 78.308575 million shares, accounting for 15% of the company's total stock capital.
There May Be Reason For Hope In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Disappointing Earnings
Liberal Arts Biotech: Report for the third quarter of 2024
Chinare Pharma (03320): China Resources Boya Bio-pharmaceutical Group's net income in the first three quarters was approximately 0.412 billion yuan, a decrease of 13.01% year-on-year.
china resources pharma (03320) announced the performance of china resources boya bio-pharmaceutical group for the first 9 months of 2024, with total operating income of approximately 12.4...
Shareholders in China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Are in the Red If They Invested Three Years Ago
Some Confidence Is Lacking In China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) As Shares Slide 26%
